CANF today
$1.51-$0.02 (-1.31%)close Nov 18, 2026Trend
DailyDowntrend (confirmed)
4 hourExpanding
1 hourExpanding
15 minSymmetric Triangle
5 minSymmetric Triangle
Daily trend turns up above $1.70
Key levels
Resistance$2.14
Resistance$1.70
Support$1.50
Latest news & SEC filings
No headlines in the last 90 days.
About Can-Fite BioPharma
Can-Fite BioPharma is a drug developer working on orally taken small molecules that act on the A3 adenosine receptor. Its three main candidates are Piclidenoson, Namodenoson, and CF602, which are being tested for oncology, hepatic, and inflammatory conditions. The company is based in Israel and has no products on the market yet.
Based on the company's 20-F filed Mar 26, 2026.
NYSE · Healthcare
Can-Fite BioPharma Ltd. (CANF)
What Is the Price Target for CANF?
SEPT Low Target
$5.00
SEPT Mid Target
$7.00
SEPT High Target
$8.00
Analyst Consensus
$7.00
Is CANF a Buy or Sell Right Now?
Thesis
- •Revenue growing -39.9% YoY with DECLINING trend — consistent growth.
Test your own strategy on CANF
Describe your strategy in plain words, then scan, alert, backtest and paper trade it on CANF with SEPT’s own market data.
Start Free Trial →Is CANF Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$7.46
0
Moat Score
NONE
1/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with CANF?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See Smart Money Data →CANF Growth Story
Revenue YoY
-39.9%
3yr Revenue CAGR
-20.6%
EPS Growth YoY
45.03%
FCF Growth YoY
-17.1%
Revenue Trend
DECLINING
Dark Pool Trades for CANF
PREVIEWRecent off-exchange (dark pool) prints for CANF: size, dollar value and side. One of the data views on SEPT, alongside its own pressure bars, swings, volume spike levels and key levels.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:06:25 | $1.50 | 1,000 | $$2K | MIDPOINT |
| 14:44:22 | $1.50 | 2,000 | $$3K | SELL |
| 14:21:53 | $1.54 | 2,635 | $$4K | SELL |
| 14:11:06 | $1.54 | 1,600 | $$2K | SELL |
| 14:11:06 | $1.54 | 1,421 | $$2K | SELL |
5 dark pool trades shown · $$13K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Can-Fite BioPharma Ltd. (CANF) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Your strategy, tested before real money.
Describe your strategy in plain words. SEPT scans, alerts, backtests and paper trades it on its own market data. SEPT provides tools only and does not tell you what to buy or sell.
Try SEPT Free for 7 Days →CANF — frequently asked questions
What is CANF stock price today?
Can-Fite BioPharma Ltd. (CANF) is at $1.51, down 1.31% (-$0.02) at the Nov 18, 2026 close.
What is the CANF price target?
The average analyst price target for CANF is $7.00, ranging from $5 to $8, based on 3 analysts.
What do analysts rate CANF?
Analyst ratings for CANF: 1 Buy, 2 Hold, 0 Sell — consensus Hold.
Did CANF beat earnings?
CANF last reported on Sep 8, 2026: EPS -$1.24 vs -$0.33 expected — a miss of 275.8%.
What are CANF support and resistance levels?
Support: $1.50. Resistance: $1.70, $2.14, $2.27.
What are insiders doing with CANF?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.